Antitumor activity of paclitaxel is significantly enhanced by a novel proapoptotic agent in non–small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Antitumor activity of paclitaxel is significantly enhanced by a novel proapoptotic agent in non–small cell lung cancer

Published:2015-04 Issue:2 Volume:194 Page:622-630
ISSN:0022-4804
Container-title:Journal of Surgical Research
language:en
Short-container-title:Journal of Surgical Research

Author:

Razi Syed S.^ORCID,Rehmani Sadiq,Li Xiaogui,Park Koji,Schwartz Gary S.,Latif Mohammed J.,Bhora Faiz Y.

Publisher

Elsevier BV

Subject

Surgery

Reference31 articles.

1. Cancer statistics, 2013;Siegel;CA Cancer J Clin,2013

2. Survival after lobectomy versus segmentectomy for stage I non-small cell lung cancer: a population-based analysis;Whitson;Ann Thorac Surg,2011

3. Emerging options for the management of non-small cell lung cancer;Binder;Clin Med Insights Oncol,2013

4. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer;Savas;J Thorac Dis,2013

5. The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era;Lwin;J Thorac Dis,2013

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. miRNAs and exosomal miRNAs in lung cancer: New emerging players in tumor progression and therapy response;Pathology - Research and Practice;2023-11

2. New Visions on Natural Products and Cancer Therapy: Autophagy and Related Regulatory Pathways;Cancers;2022-11-26

3. Blocking circ_0010235 suppresses acquired paclitaxel resistance of non-small cell lung cancer by sponging miR-512-5p to modulate FAM83F expression;Anti-Cancer Drugs;2022-09-29

4. Establishing combination PAC‐1 and TRAIL regimens for treating ovarian cancer based on patient‐specific pharmacokinetic profiles usingin silicoclinical trials;Computational and Systems Oncology;2022-06

5. Trifluoperazine and Its Analog Suppressed the Tumorigenicity of Non-Small Cell Lung Cancer Cell; Applicability of Antipsychotic Drugs to Lung Cancer Treatment;Biomedicines;2022-04-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3